Carol Schwanebeck, N.P. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 350 Crossgates Blvd, Brandon, MS 39042 Phone: 601-679-1665 |
Dr. Andrew Spencer Anfanger, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 350 Crossgates Blvd, Brandon, MS 39042 Phone: 601-856-2677 |
Dr. John Joseph Cook, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 350 Crossgates Blvd, Brandon, MS 39042 Phone: 601-366-3222 |
Dr. David Kennedy Stone, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 102 Pine Ct, Brandon, MS 39047 Phone: 601-992-1200 |
Salvador Arceo Iii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 350 Crossgates Blvd, Brandon, MS 39042 Phone: 601-898-1663 |
Deborah Miles Ables, N.P. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 350 Crossgates Blvd, Brandon, MS 39042 Phone: 601-845-8039 |
News Archive
This year's International Microbicides Conference, held this week in Sydney, "will be the last of its kind" because "from 2014 onwards, it is planned, a single biennial conference on all aspects of HIV prevention will be held," according to an aidsmap news story.
Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).
MBF Healthcare Partners, L.P., a middle market healthcare focused private equity firm, announced it has sold Medical Specialties Distributors, LLC, to private equity firm Water Street Healthcare Partners.
A trio of studies being published today in the journals Science and Cell describes advances toward the development of an HIV vaccine. The three study teams all demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.
› Verified 1 days ago